- Home
- ERNA vs APRE Comparison
ERNA vs APRE Comparison
Compare ERNA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | APRE |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ERNA | APRE |
|---|---|---|
| Price | $0.24 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.2M | 92.5K |
| Earning Date | 03-16-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.55 |
| 52 Week High | $3.00 | $2.34 |
Technical Indicators
Market Signals| Indicator | ERNA | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 25.45 | 39.23 |
| Support Level | $0.16 | $0.55 |
| Resistance Level | $0.35 | $0.95 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 11.39 | 7.47 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.